La FDA a approuvé l’utilisation de l’immunothérapie allogénique par cellules T régulatrices, HSPC et T-cell-vldq, pour le traitement des hémopathies malignes de l’adulte par transplantation de cellules souches hématopoïétiques de donneur compatible.
L'extension .gov indique qu'il s'agit d'un site web officiel.
Contenu integral de l article
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
الاسئلة الشائعة
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
